News

Capricor Therapeutics Advances in DMD Treatment with FDA BLA

Capricor Therapeutics Advances in DMD Treatment with FDA BLA

Capricor Therapeutics Takes Significant Step with FDA Submission

-If approved, deramiocel would be the first therapy for Duchenne muscular dystrophy cardiomyopathy-

-BLA submission triggers a $10 million milestone payment to Capricor from Nippon Shinyaku-

Capricor Therapeutics (NASDAQ: CAPR), a pioneering biotechnology company originating from an innovative background in cell and exosome-based therapeutics, has recently completed a major milestone by submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). This submission seeks full approval for deramiocel, an investigational therapy designed to treat patients suffering from Duchenne muscular dystrophy (DMD) cardiomyopathy.

Impact of the BLA Submission

Linda Marbán, Ph.D., the CEO of Capricor, emphasized the importance of this application: "The submission of the BLA marks a pivotal moment for Capricor and the families impacted by DMD. This is the result of extensive research and dedication to providing a transformative therapy for those in need." With multiple clinical trials demonstrating deramiocel's ability to potentially mitigate cardiac concerns related to DMD, the company looks forward to collaborating closely with the FDA during the review process.

The Regulatory Pathway and Milestone Payments

The completion of the rolling BLA was anticipated and confirmed as per the company's previous statements made in late December. Capricor has backed this application with data from the Phase 2 HOPE-2 trial and its Open Label Extension (OLE) trials. This data is benchmarked against historical datasets funded and published by the FDA that outline the cardiac implications of DMD and its disease progression biomarkers.

In addition to the milestone of submitting the BLA, Capricor will also receive a payment of $10 million from Nippon Shinyaku Co., Ltd. as part of their collaboration for commercialization in the United States.

Designations Holding Hope for Patients

Deramiocel comes with significant designations, having obtained the Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA). The regulatory journey is further supported by the Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., alongside the Advanced Therapy Medicinal Product (ATMP) designation in Europe. Should deramiocel secure FDA approval, Capricor may be eligible for a Priority Review Voucher due to its previous rare pediatric disease designation.

Understanding Deramiocel and Its Mechanism

Deramiocel, scientifically referenced as CAP-1002, utilizes allogeneic cardiosphere-derived cells (CDCs). These specialized stromal cells have garnered attention due to their immunomodulatory and regenerative properties observed in rigorous clinical and preclinical studies. The mode of action revolves around the secretion of exosomes by CDCs, which target macrophages and encourage a switch to a healing state rather than a pro-inflammatory one.

This therapy has significant implications as CDCs have already been part of over 100 peer-reviewed publications and have been administered to more than 200 human subjects across numerous clinical trials, illustrating its potential and the wide array of studies backing its efficacy.

Addressing Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a severe genetic ailment linked to progressive skeletal muscle weakness and severe inflammation affecting the skeletal, cardiac, and respiratory functions. Individuals diagnosed with DMD have a challenging prognosis and often face mortality by their thirties. It is a rare condition, affecting approximately one in 3,500 male births, accumulating around 15,000-20,000 cases in the U.S.

Capricor Therapeutics: A Focus on Innovation

Capricor Therapeutics, Inc. (NASDAQ: CAPR), stands at the forefront of biotechnology with a mission focused on advancing innovative cell and exosome-based therapeutics, redefining the treatment landscape for rare diseases. The firm’s flagship product candidate, deramiocel, exemplifies their commitment to addressing urgent medical needs, particularly in the area of DMD. Beyond deramiocel, Capricor is exploring its proprietary StealthX™ platform, targeting various therapeutic applications including vaccinology and targeted drug delivery, widening their scope for innovation.

Staying Connected

For any inquiries or additional information, individuals can connect with Capricor through social media platforms like Facebook, Instagram, and Twitter, or visit the official Capricor website. Additionally, key contacts for media relations and company inquiries are also accessible for more insights.

Frequently Asked Questions

What is the significance of the BLA submission for Capricor?

The BLA submission is a major milestone in seeking approval for deramiocel, an important therapeutic option for patients with DMD.

How does deramiocel work?

Deramiocel utilizes cardiosphere-derived cells that release exosomes facilitating healing by modulating macrophage activity.

What are the designations received by deramiocel?

Deramiocel has received Orphan Drug Designation and RMAT designation, which expedite its review and approval process.

What other areas is Capricor exploring?

Capricor is also working on its StealthX™ platform for targeted delivery and diverse therapeutic applications.

How can I stay updated with Capricor Therapeutics?

Stay connected with Capricor via their website and social media channels for the latest updates and information.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 45

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights into Carvana's Growing Options Market Activity

Updated Category News Views 105

Carvana's Options Market Activity Investors with substantial capital are displaying a bullish sentiment towards Carvana Co (NYSE: CVNA). This developing trend in the options market is noteworthy and shouldn't be overlooked by market participants. Recent analyses have revealed an intriguing series of activities that hint at significant upcoming developments for Carvana....

Continue Reading
Road Warrior Expands Network with Big Acquisitions

Updated Category News Views 30

A Heavy-Duty Play: Road Warrior's Big Moves You might think in the world of heavy-duty parts and service, things move like a freight train—slow and steady. But here comes Road Warrior Parts & Service, full steam ahead with a string of acquisitions that are shaking up the landscape. If you've been snoozing on this sector, it's time to wake up. The Acquisitions That Are...

Continue Reading
Foresight Group Commences Strategic Share Buyback Programme

Updated Category News Views 358

Foresight Group Commences Strategic Share Buyback Programme Foresight Group Holdings Limited (LSE: FSG), a well-respected leader in investment management for real assets, is pleased to announce a new initiative as part of its ongoing commitment to creating shareholder value. This new share buyback programme, announced recently, underscores its proactive approach to...

Continue Reading
Carvana's New Delivery Service Lifts Stock Prices Significantly

Updated Category News Views 164

Overview of Carvana's Recent Stock Movement Carvana Co (NYSE: CVNA) has seen its stock rise as it introduces new service options. Recently, the company extended its same-day vehicle delivery feature to customers in the San Diego area, marking a significant enhancement in its operations. By allowing locals to receive their purchased vehicles on the same day they place an...

Continue Reading
AI-Powered Travel Transformation in Norway Revealed

Updated Category News Views 130

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Continue Reading